（来源： 互联网 ）
时时彩网络平台 www.qlgr.net 据外媒消息，MeritMedical（NYSE: MMSI）近日表示，以1亿美元收购BD医疗(NYSE:BDX) 和 巴德医疗(NYSE: BCR)的软组织活检资产（据反垄断法规定，BD医疗和巴德公司需要通过剥离旗下活组织检查业务来完成他们240亿美元的合并）。
MeritMedical to pay $100m for Bard, BD biopsy assets
MeritMedical (NSDQ:MMSI) said today that it agreed topay $100 million for soft tissue biopsy assets Becton Dickinson (NYSE:BDX) and C.R. Bard (NYSE:BCR) need to sell to consummatetheir $24 billion merger.
The deal coversBD’s Achieve and Temno biopsy systems and Tru-Cut biopsy needles, plusBard’s Aspira pleural effusion drainage and peritoneal drainage systems,South Jordan, Utah-based Merit said.
“We believe this is a perfect fit for Merit,”chairman & CEO Fred Lampropoulos said in prepared remarks. “These productsare well established with an installed base and complement Merit’s CorVocetfull core biopsy system and our recently-acquired bone biopsy products.
“There are also a number of markets in whichMerit has direct representation that will be expanded to include the acquiredproducts, as well as new markets which we plan to develop,” Lampropoulos said.“In summary, we believe this transaction will provide complementary high-marginproducts, increased use of our existing facilities, market expansionopportunities, accretive margins, profits and our existing sales forceutilization.”
“Today’s announcement of ourintent to divest two product lines is another step forward in the regulatoryreview process of BD’s planned acquisition of Bard,” added BD chairman & CEO VincentForlenza. “We continue to expect that the BD and Bard transaction will close inthe fourth calendar quarter of 2017, subject to customary closing conditionsand additional regulatory approvals, including the U.S. Federal TradeCommission and other regulatory bodies.”
Merit said it plans to financethe acquisitions with an existing credit revolver. The biopsy assets areexpected to add $42 million to $48 million in annual revenues and 10￠ to19￠ in adjusted earnings per share during fiscal 2018.
In September BD and Bard agreed to unspecified concessions to address Europeananti-trust concerns, after Bard shareholders overwhelmingly approved the $24 billionmerger inAugust. The $317-per-share deal, which was announced last April, is expected to close duringthe fourth quarter, the companies have said. In June, the FTC asked for more information on themerger,adding 30 days to the timeline for closing the deal.